The IPO application of Chinese genomics powerhouse BGI's bid to list on the Chi-Next board of the Shenzhen Stock Exchange has been terminated, as Chinese securities regulator cited incomplete documentation as a reason for inability to proceed with its review. The event adds yet another twist to BGI's pursuit of a stock float, after years […]

Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.